Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

伦瓦提尼 医学 索拉非尼 肝细胞癌 内科学 肿瘤科 核医学
作者
Riccardo Lencioni,Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Ann-Lii Cheng,Fabio Piscaglia,Guohong Han,Masafumi Ikeda,Krzysztof Simon,Dmitry Komov,Xuenong Ouyang,T.R. Jeffry Evans,Max Sung,Terri A. Binder,Andrew Damon,Silvija Kraljevic,Ren Min,Baek-Yeol Ryoo
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
被引量:1
标识
DOI:10.1200/jco.2018.36.4_suppl.345
摘要

345 Background: LEN showed treatment effect on OS by statistical demonstration of noninferiority to SOR in a phase 3 study in pts with uHCC, with significant improvement ( P < 0.00001) in median PFS (7.4 vs 3.7 mos; HR: 0.66; 95% CI, 0.57−0.77), median TTP (8.9 vs 3.7 mos; HR: 0.63. 95% CI, 0.53−0.73), and ORR (24% vs 9%). Tumor assessments were by investigator review (IR) per modified RECIST (mRECIST). We present IIR results to assess concordance for IR vs IIR and mRECIST vs RECIST 1.1 by IIR. Methods: In this open-label study, pts with uHCC, ≥ 1 measurable target lesion, BCLC stage B or C, Child-Pugh class A, ECOG PS ≤ 1, and no prior systemic therapy were randomized 1:1 to LEN (body weight ≥60 kg: 12 mg/d; <60 kg: 8 mg/d) or SOR 400 mg twice daily. Primary endpoint was OS. Secondary efficacy endpoints were PFS, TTP, and ORR by mRECIST. IR tumor assessments were done every 8 wks. Post hoc exploratory blinded IIR studies were done using mRECIST and RECIST 1.1 (first timepoint at wk 8). Results: A total of 954 pts enrolled (LEN: 478; SOR: 476), of which 952 (99.8%) pts were IIR assessable (table). Adjudication rate (AR; percentage of cases adjudicated due to disagreement) for timepoint of PD was similar for mRECIST (47%) and RECIST 1.1 (45%); for responder (CR or PR)/nonresponder (SD, PD, or not evaluable [NE]), it was 32% for mRECIST and 17% for RECIST 1.1. PFS and TTP results were nearly the same per mRECIST by IIR as by IR and the same by IIR per mRECIST and RECIST 1.1. Very good concordance was seen between IIR and IR in best overall response (BOR) per mRECIST with the greatest discordance due to more pts being assessed as PR than SD for LEN. Conclusions: IIR supports IR results. ORR was higher in both arms by IIR vs IR but relative ORR was preserved in LEN vs SOR. Higher AR for IIR per mRECIST on response may be due to the greater number of responders or disease complexity. Median PFS and TTP were the same by IIR per mRECIST and RECIST 1.1, showing these data can be compared between methods. Clinical trial information: NCT01761266. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
时光里发布了新的文献求助10
1秒前
小齐发布了新的文献求助10
2秒前
oncoma完成签到 ,获得积分10
3秒前
小张同学完成签到 ,获得积分10
3秒前
5秒前
5秒前
6秒前
6秒前
7秒前
猪猪发布了新的文献求助10
7秒前
7秒前
8秒前
maolao发布了新的文献求助10
9秒前
9秒前
9秒前
Momo发布了新的文献求助10
10秒前
碧蓝巧荷发布了新的文献求助10
10秒前
11秒前
11秒前
十七发布了新的文献求助10
11秒前
12秒前
耍酷的白玉完成签到,获得积分10
12秒前
hll发布了新的文献求助10
12秒前
寒风完成签到,获得积分10
13秒前
weixin112233发布了新的文献求助10
15秒前
Orange应助发嗲的高跟鞋采纳,获得10
15秒前
ShengQ发布了新的文献求助10
16秒前
17秒前
17秒前
幽默的谷梦完成签到,获得积分10
17秒前
LaKers发布了新的文献求助10
18秒前
可爱的函函应助后来采纳,获得10
18秒前
Jasper应助科研通管家采纳,获得10
18秒前
上官若男应助科研通管家采纳,获得10
18秒前
852应助科研通管家采纳,获得10
18秒前
嗯哼应助科研通管家采纳,获得20
19秒前
英俊的铭应助科研通管家采纳,获得10
19秒前
嗯哼应助科研通管家采纳,获得20
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248346
求助须知:如何正确求助?哪些是违规求助? 2891768
关于积分的说明 8268557
捐赠科研通 2559696
什么是DOI,文献DOI怎么找? 1388596
科研通“疑难数据库(出版商)”最低求助积分说明 650772
邀请新用户注册赠送积分活动 627744